Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vaxart, Inc.
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
Altimmune’s hopes of bringing a nasal COVID-19 vaccine to market have been dashed, but it is pivoting to novel peptide-based therapies.
Novavax said it would start shipping supplies of its vaccine to Europe starting in late 2021, while Vaxart delayed the start of its Phase II study due to issues with Emergent BioSolutions. Meanwhile, Roche India received an EUA for Regeneron's antibody cocktail
- Drug Delivery
- Other Names / Subsidiaries
- Aviragen Therapeutics, Inc. (Anaconda Pharma SAS
- Biota Holdings Limited
- Biota Pharmaceuticals, Inc.
- Nabi Biopharmaceuticals)